According to ITUS CEO Dr. Amit Kumar, "There is potential for tremendous synergy from the complementary expertise of ITUS and Serametrix. We believe that the additional capabilities provided by the Serametrix alliance will allow ITUS Corporation to expand the commercial opportunities of Cchek.

“Also, we believe that the application of our artificial intelligence expertise to Serametrix's flow cytometry immuno-profiling services will allow Serametrix to offer unique and superior capabilities unavailable to other laboratories."

ITUS boasts that it is harnessing the body's immune system in the fight against cancer. Its wholly-owned subsidiary, Anixa Diagnostics Corporation, is developing the Cchek platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy.

Shares in ITUS leaped 49 cents, or 15%, to $3.75, only minutes away from Monday’s closing bell, within a 52-week range of 60 cents to $6.43.